HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences gets final nod for Cevimeline Hydrochloride Capsules
Mar-13-2026

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Cevimeline Hydrochloride Capsules 30 mg, (USRLD: Evoxac Capsules, 30 mg).

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjogren’s syndrome. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion. Cevimeline hydrochloride 30 mg capsules will be produced at the Group’s manufacturing facility at SEZ-II, Ahmedabad.

Cevimeline Hydrochloride Capsules 30mg had annual sales of $26.9 million. (IQVIA MAT Jan-26). The group now has 436 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>